methyl 2-isocyanatosulfonylbenzoate

We are methyl 2-isocyanatosulfonylbenzoate CAS:74222-95-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 74222-95-0
Product Name: methyl 2-isocyanatosulfonylbenzoate
Other Name:
methyl 2-isocyanatosulfonylbenzoate
2-carbomethoxyphenylsulfonyl isocyanate
2-carbomethoxybenzenesulfonyl isocyanate
2-carboxymethylsulfonyl isocyanate
o-methoxycarbonylbenzenesulfonyl isocyanate
Methyl 2-[(oxomethylene)sulfamoyl]benzoate
2-(Isocyanatosulfonyl)benzoic acid methyl ester
 
Density: 1.4±0.1 g/cm3
Boiling Point: 362.0±25.0 °C at 760 mmHg
Molecular Formula: C9H7NO5S
Molecular Weight: 241.221
Flash Point: 172.7±23.2 °C
Exact Mass: 241.004486
PSA: 98.25000
LogP: 1.95
Vapour Pressure: 0.0±0.8 mmHg at 25°C
Index of Refraction: 1.570
 
Specification
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Ethametsulfuron-Methyl CAS: 97780-06-8.
Intermediates of Sulfometuron-Methyl CAS: 74222-97-2.
Intermediates of Metsulfuron-Methyl CAS: 74223-64-6.
Be used as pesticide intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

methyl 2-isocyanatosulfonylbenzoate


Related News: Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.3-Bromo-2-fluoro-5-nitropyridine CAS:1868-58-2 Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.Ácido 3- (4-clorofenil) glutámico CAS:1141-23-7 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.3-Chloropropyne CAS:624-65-7 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.

Related Products
Product Name
3-Fluoro-4-chlorotoluene View Details
N-[[(1,1-Dimethylethyl)Amino]Carbonyl]-3-Methyl-L-Valine View Details
2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid View Details
Ethyl 5-oxo-1-phenyl-2-pyrazoline-3-carboxylate manufacturer Nesiritide acetate manufacturer 2,3-Diethyl-5-methylpyrazine manufacturer 3,5-Dichlorobenzaldehyde manufacturer 1-Chlorotetradecane manufacturer